Prevest Denpro

Prevest Denpro reported a consolidated revenue of INR 67.09 crores for FY25, marking a 13.6% growth over the previous year's INR 59.29 crores. Domestic sales contributed significantly with a 13% increase, while exports grew by 10% year-on-year. The company maintained strong operational efficiency, with EBITDA margins holding steady at 38.98% for FY25, compared to 38.30% last year. Net profit after tax (PAT) for the year stood at INR 18.15 crores, reflecting a 12.51% growth and a healthy PAT margin of 27.06%. The fourth quarter was particularly strong, with revenue reaching INR 19.53 crores, a 21.79% jump from Q3, and EBITDA margins at 39.03%.

The company has made a bold move into digital dentistry, building on its 3D resin portfolio launched last year. This involves developing advanced 3D printers and scanners, combining in-house R&D with strategic partnerships with global suppliers. Management believes digital dentistry will be a significant growth area, with the global market projected to reach $17.9 billion by 2033, and sees this as a natural progression for the company. They aim to offer a complete end-to-end digital workflow solution for dental clinics and labs.

Prevest Denpro is actively expanding its international footprint, with exports growing 10% this year. A key focus is the US market, which accounts for approximately 40% of the global dental market. To enhance brand recognition and overcome the 'Made in India' perception, the company incorporated Axiodent Incorporation in the US, which saw its revenue grow by 14% this year. They are also pursuing private labeling partnerships and contract manufacturing opportunities in the US, leveraging their FDA-approved products.

The R&D team is focused on innovation and translation, successfully developing three new cutting-edge biomaterials: Crysta Axis (strontium-enriched restorative material), Caries Cure SDF (silver diamine fluoride system), and Crysta LC RMGI (resin-modified glass ionomer). These products are 100% indigenously developed. The company plans to launch 4 to 5 new products in FY26, emphasizing performance, safety, and clinical excellence. Additionally, they are scaling up production of core biomaterials like hydroxyapatite and tricalcium phosphate for internal use and global commercialization to other manufacturers and medical device suppliers.

While FY25 saw 13.6% revenue growth, it was lower than the 30% growth rates seen post-IPO, attributed to market deflation, foreign exchange crises in some international markets, and the slower-than-anticipated uptake of the Oradox product line, which contributed only INR 50 lakhs. Despite these challenges, management remains optimistic, aspiring for 25-30% growth in the coming year, driven by stabilization in international markets, momentum in digital dentistry, and the US operations. They emphasize a long-term view, prioritizing consistent profitable growth over unsustainable short-term gains.

The company has focused on strengthening its fundamentals by implementing lean manufacturing principles, upgrading ERP systems, and optimizing its supply chain network. These initiatives have resulted in better asset utilization, reduced working capital, and improved production flexibility. This focus on efficiency helped maintain EBITDA margins at 38.98% for FY25 despite inflationary pressures on raw materials and logistics. Management stated that director salaries have not increased in the last 5 years and are commensurate with market standards, indicating a focus on business growth rather than cost-cutting in this area.